Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Ramcon A/S (Denmark) Distributes and Supports Anagnostics Products

Published: Thursday, April 12, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Ramcon covers the Northern European countries and serves customers in Denmark, Sweden, Norway, Finland and Iceland with a highly specialized sales force.

Since February of this year Danish Ramcon A/S offers Anagnostics’ drugs of abuse testing and pharmacogenetics solutions as distribution partner.

During the course of the year, further products, especially relating to severe infection testing will follow.

Establishing the innovative products in the Northern European Countries as well as competent and first class customer support are common goals of the partners.

“The decision to partner with Ramcon simply made sense, since Ramcon already specializes in tests and systems for in vitro diagnostics and life sciences with a loyal and broad customer base. Ramcon focuses on first class end-user service and support. Therefore both organizations perfectly fit together”, summarizes Markus Jaquemar, CMO Anagnostics Bioanalysis GmbH.

Jesper Hardt, CEO of Ramcon A/S, is looking forward to a successful partnership: “We can see a clear trend towards multiplex testing. Anagnostics perfectly responds to these market needs with the hyborg system and its testing menu. The fast and efficient response to actual drug consumption will secure access to drug therapy institutions. The efficient and highly sensitive pharmacogenetics test will benefit small or mid-sized pathological entities.”

Multiplex Diagnostics with Focus on Drugs of Abuse Screening, Pharmacogenetics (Oncology) and Serve Infection Testing Anagnostics Bioanalysis with its headquarters in St. Valentin (Austria) is specialized in developing systems, devices and tests in drugs of abuse screening, pharmacogenetics (oncology) and tests for diagnosing severe infections.

With the unique ability to perform protein as well as DNA based assays the hyborg system offers a testing platform meeting needs of personalized medicine and integrated diagnostics.

Anagnostics was established in 2005 by Bernhard Ronacher, a molecular genetics scientist. A cylindrical microarray - the hybcell - is the core of the patented multiplex technology.

Combined with the hyborg analysis system multi-parameter assays are performed in a fully automated manner.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Anagnostics Enters Sales Cooperation with Analis S.A.
Company enters cooperation for Belgium and Luxembourg.
Monday, December 10, 2012
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos